H.R. 3

Alliance for Aging Research on First 10 Part D Drugs Subject to Medicare Price-Setting: Today is Not a Reason to Celebrate

Retrieved on: 
Wednesday, August 30, 2023

WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- This morning, the Centers for Medicare and Medicaid Services (CMS) announced the first 10 Part D drugs to be subject to Medicare price-setting .

Key Points: 
  • WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- This morning, the Centers for Medicare and Medicaid Services (CMS) announced the first 10 Part D drugs to be subject to Medicare price-setting .
  • Sue Peschin, MHS, President and CEO at the Alliance for Aging Research, issued the following statement in response:
    The process instead captures drugs that serve large numbers of beneficiaries at modest cost rather than high-cost drugs.
  • "Staging a celebration to announce the first 10 Part D drugs subject to CMS' government price-setting in the Medicare program is macabre and misleading.
  • We have opposed every Medicare price-setting proposal since 2019 because their value frameworks combine analyses of both cost-effectiveness and budget impact.

Report from Incubate Policy Lab and Charles River Associates Finds Congressional Budget Office Underestimates Negative Impact of Drug Pricing Legislation

Retrieved on: 
Wednesday, October 20, 2021

3, would have a far greater negative impact than estimated by the Congressional Budget Office.

Key Points: 
  • 3, would have a far greater negative impact than estimated by the Congressional Budget Office.
  • "Our new report captures what the Congressional Budget Office failed to incorporate: investor behavior.
  • The advocacy organization recently launched its research arm, Incubate Policy Lab, which explores various policy initiatives and potential effects on the biopharmaceutical industry.
  • AboutCharles River Associates: Charles River Associates is a leading global consulting firm specializing ineconomic, financial, and management consulting services.

Regional Business Leaders Warn of Tremendous Loss of Jobs, Economic Output from H.R. 3

Retrieved on: 
Friday, September 3, 2021

Citing a recent study, these groups warned of a resulting regional job loss totaling 131,500 as well as $35.4 billion in lost economic output annually combined between the three states if the bill were enacted.

Key Points: 
  • Citing a recent study, these groups warned of a resulting regional job loss totaling 131,500 as well as $35.4 billion in lost economic output annually combined between the three states if the bill were enacted.
  • In addition to the potential job and economic impact, the letter also forewarned of significant decreases in construction activity, tax revenue, charitable donations, vendor spending and other adverse consequences.
  • The business leaders urged federal representatives in the three states to oppose H.R.
  • This bill will not lower costs for patients, but it will jeopardize patient access and the future of medical innovation.